Display options
Cite
Longino AA, Paul R, Wang Y, et al. HIV Disease Dynamics and Markers of Inflammation and CNS Injury During Primary HIV Infection and Their Relationship to Cognitive Performance. J Acquir Immune Defic Syndr. 2022;89(2):183-190doi: 10.1097/QAI.0000000000002832.
Longino, A. A., Paul, R., Wang, Y., Lama, J. R., Brandes, P., Ruiz, E., Correa, C., Keating, S., Spudich, S. S., Pilcher, C., Vecchio, A., Pasalar, S., Bender Ignacio, R. A., Valdez, R., Dasgupta, S., Robertson, K., & Duerr, A. (2022). HIV Disease Dynamics and Markers of Inflammation and CNS Injury During Primary HIV Infection and Their Relationship to Cognitive Performance. Journal of acquired immune deficiency syndromes (1999), 89(2), 183-190. https://doi.org/10.1097/QAI.0000000000002832
Longino, August A, et al. "HIV Disease Dynamics and Markers of Inflammation and CNS Injury During Primary HIV Infection and Their Relationship to Cognitive Performance." Journal of acquired immune deficiency syndromes (1999) vol. 89,2 (2022): 183-190. doi: https://doi.org/10.1097/QAI.0000000000002832
Longino AA, Paul R, Wang Y, Lama JR, Brandes P, Ruiz E, Correa C, Keating S, Spudich SS, Pilcher C, Vecchio A, Pasalar S, Bender Ignacio RA, Valdez R, Dasgupta S, Robertson K, Duerr A. HIV Disease Dynamics and Markers of Inflammation and CNS Injury During Primary HIV Infection and Their Relationship to Cognitive Performance. J Acquir Immune Defic Syndr. 2022 Feb 01;89(2):183-190. doi: 10.1097/QAI.0000000000002832. PMID: 34629415.
Copy Download .nbib Format: NLM
Share it on

J Acquir Immune Defic Syndr. 2022 Feb 01;89(2):183-190. doi: 10.1097/QAI.0000000000002832.

HIV Disease Dynamics and Markers of Inflammation and CNS Injury During Primary HIV Infection and Their Relationship to Cognitive Performance.

Journal of acquired immune deficiency syndromes (1999)

August A Longino, Robert Paul, Yixin Wang, Javier R Lama, Peter Brandes, Eduardo Ruiz, Cecilia Correa, Sheila Keating, Serena S Spudich, Christopher Pilcher, Alyssa Vecchio, Siavash Pasalar, Rachel A Bender Ignacio, Rogelio Valdez, Sayan Dasgupta, Kevin Robertson, Ann Duerr

Affiliations

  1. University of Colorado, Denver, CO.
  2. University of Missouri, St. Louis, MO.
  3. Fred Hutchinson Cancer Research Center, Seattle, WA.
  4. Asociacion Civil Impacta Salud y Educacion, Lima, Peru.
  5. GigaGen, San Francisco, CA.
  6. Yale University, New Haven, CT.
  7. University of California, San Francisco, CA.
  8. University of North Carolina at Chapel Hill, Chapel Hill, NC.
  9. University of Washington, Seattle, WA.
  10. Case Western Reserve University, Cleveland, OH; and.

PMID: 34629415 DOI: 10.1097/QAI.0000000000002832

Abstract

INTRODUCTION: Early systemic and central nervous system viral replication and inflammation may affect brain integrity in people with HIV, leading to chronic cognitive symptoms not fully reversed by antiretroviral therapy (ART). This study examined associations between cognitive performance and markers of CNS injury associated with acute HIV infection and ART.

METHODS: HIV-infected MSM and transgender women (average age: 27 years and education: 13 years) enrolled within 100 days from the estimated date of detectable infection (EDDI). A cognitive performance (NP) protocol was administered at enrollment (before ART initiation) and every 24 weeks until week 192. An overall index of cognitive performance (NPZ) was created using local normative data. Blood (n = 87) and cerebrospinal fluid (CSF; n = 29) biomarkers of inflammation and neuronal injury were examined before ART initiation. Regression analyses assessed relationships between time since EDDI, pre-ART biomarkers, and NPZ.

RESULTS: Adjusting for multiple comparisons, shorter time since EDDI was associated with higher pre-ART VL and multiple biomarkers in plasma and CSF. NPZ scores were within the normative range at baseline (NPZ = 0.52) and at each follow-up visit, with a modest increase through week 192. Plasma or CSF biomarkers were not correlated with NP scores at baseline or after ART.

CONCLUSIONS: Biomarkers of CNS inflammation, immune activation, and neuronal injury peak early and then decline during acute HIV infection, confirming and extending results of other studies. Neither plasma nor CSF biomarkers during acute infection corresponded to NP scores before or after sustained ART in this cohort with few psychosocial risk factors for cognitive impairment.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

  1. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS. 2010;24:1243–1250. - PubMed
  2. Sacktor N, Skolasky RL, Seaberg E, et al. Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study. Neurology. 2016;86:334–340. - PubMed
  3. Rubin LH, Saylor D, Nakigozi G, et al. Heterogeneity in neurocognitive change trajectories among people with HIV starting antiretroviral therapy in Rakai, Uganda. J Neurovirol. 2019;25:800–813. - PubMed
  4. Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75:2087–2096. - PubMed
  5. Eggers C, Arendt G, Hahn K, et al. HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol. 2017;264:1715–1727. - PubMed
  6. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69:1789–1799. - PubMed
  7. Kore I, Ananworanich J, Valcour V, et al. Neuropsychological impairment in acute HIV and the effect of immediate antiretroviral therapy. J Acquir Immune Defic Syndr. 2015;70:393–399. - PubMed
  8. Moore DJ, Letendre SL, Morris S, et al. Neurocognitive functioning in acute or early HIV infection. J Neurovirol. 2011;17:50–57. - PubMed
  9. Lama JR, Brezak A, Dobbins JG, et al. Design strategy of the Sabes study: diagnosis and treatment of early HIV infection among men who have sex with men and transgender women in Lima, Peru, 2013-2017. Am J Epidemiol. 2018;187:1577–1585. - PubMed
  10. Massanella M, Bender Ignacio R, Lama JR, et al. Long-term effects of early antiretroviral initiation on HIV reservoir markers: a longitudinal analysis of the MERLIN clinical study. The Lancet Microbe. 2021;2:E198–E209. - PubMed
  11. Grebe E, Facente SN, Bingham J, et al. Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool. BMC Infect Dis. 2019;19:894. - PubMed
  12. Robertson K, Jiang H, Evans SR, et al. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. J Neurovirol. 2016;22:472–478. - PubMed
  13. Robertson K, Kumwenda J, Supparatpinyo K, et al. A multinational study of neurological performance in antiretroviral therapy-naive HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol. 2011;17:438–447. - PubMed
  14. Chowdhury F, Williams A, Johnson P. Validation and comparison of two multiplex technologies, Luminex and Mesoscale Discovery, for human cytokine profiling. J Immunol Methods. 2009;340:55–64. - PubMed
  15. Nayak S, Acharjya B. VDRL test and its interpretation. Indian J Dermatol. 2012;57:3–8. - PubMed
  16. Ferreira JA. The Benjamini-Hochberg method in the case of discrete test statistics. Int J Biostat. 2007;3:Article 11. - PubMed
  17. Schröck A, Wurst FM, Thon N, et al. Assessing phosphatidylethanol (PEth) levels reflecting different drinking habits in comparison to the alcohol use disorders identification test–C (AUDIT-C). Drug Alcohol Depend. 2017;178:80–86. - PubMed
  18. Chan P, Patel P, Hellmuth J, et al. Distribution of human immunodeficiency virus (HIV) ribonucleic acid in cerebrospinal fluid and blood is linked to CD4/CD8 ratio during acute HIV. J Infect Dis. 2018;218:937–945. - PubMed
  19. Lindbäck S, Karlsson AC, Mittler J, et al. Viral dynamics in primary HIV-1 infection. Karolinska institutet primary HIV infection study group. AIDS. 2000;14:2283–2291. - PubMed
  20. Robertson K, Fiscus S, Kapoor C, et al. CSF, plasma viral load and HIV associated dementia. J Neurovirol. 1998;4:90–94. - PubMed
  21. Hellmuth J, Slike BM, Sacdalan C, et al. Very early initiation of antiretroviral therapy during acute HIV infection is associated with normalized levels of immune activation markers in cerebrospinal fluid but not in plasma. J Infect Dis. 2019;220:1885–1891. - PubMed
  22. Sereti I, Krebs SJ, Phanuphak N, et al. Persistent, albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection. Clin Infect Dis. 2017;64:124–131. - PubMed
  23. Teigler JE, Leyre L, Chomont N, et al. Distinct biomarker signatures in HIV acute infection associate with viral dynamics and reservoir size. JCI Insight. 2018;3:e98420. - PubMed
  24. Spudich S, Gisslen M, Hagberg L, et al. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden. J Infect Dis. 2011;204:753–760. - PubMed
  25. Suh J, Sinclair E, Peterson J, et al. Progressive increase in central nervous system immune activation in untreated primary HIV-1 infection. J Neuroinflammation. 2014;11:199. - PubMed
  26. Byrd DA, Fellows RP, Morgello S, et al. Neurocognitive impact of substance use in HIV infection. J Acquir Immune Defic Syndr. 2011;58:154–162. - PubMed
  27. Kabuba N, Menon JA, Franklin DR, et al. Effect of age and level of education on neurocognitive impairment in HIV positive Zambian adults. Neuropsychology. 2018;32:519–528. - PubMed
  28. Chan P, Kerr SJ, Kroon E, et al. Cognitive trajectories after treatment in acute HIV infection. AIDS. 2021;35:883–888. - PubMed
  29. Kennedy CA, Zerbo E. HIV-related neurocognitive disorders and drugs of abuse: mired in confound, surrounded by risk. Curr Addict Rep. 2014;1:229–326. - PubMed
  30. Morgan EE, Woods SP, Smith C, et al. Lower cognitive reserve among individuals with syndromic HIV-associated neurocognitive disorders (HAND). AIDS Behav. 2012;16:2279–2285. - PubMed
  31. Stern RA, Silva SG, Chaisson N, et al. Influence of cognitive reserve on neuropsychological functioning in asymptomatic human immunodeficiency virus-1 infection. Arch Neurol. 1996;53:148–153. - PubMed

Publication Types

Grant support